GFPT2 and neoplasm: In order to validate expression of c-Myc on the protein level in subtype 2 of LMS, we performed IHC with a monoclonal antibody against c-Myc on 58 of the 59 tumor specimens that had been used for the transcriptomic analysis and GFPT2 protein expression analysis (Fig. 1b).